Internal Medicine, Hematology & Oncology · Grand Rapids, MI
NPI
1750347290
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
145 Michigan St NE Ste 3100
Grand Rapids, MI, 49503
Phone (616) 954-9800
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.7M
161,378 services
Medicare patients, 2024
518
Average age 72
Drug cost, 2024
$20.0M
4,111 prescriptions
Company payments, 2025
$1,672
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Brett T Brinker was code J9144 (injection, daratumumab, 10 mg and hyaluronidase-fihj), 16,200 times for 19 patients. In total Brett T Brinker billed 161,378 services in 212 codes, and Medicare paid $3.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-13.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 16,200 | 19 | $39.35 | $638K |
| J9145 Injection, daratumumab, 10 mg | Office | 5,695 | 11 | $49.32 | $281K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,790 | 18 | $35.92 | $136K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,760 | 14 | $31.55 | $87K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,688 | 59 | $0.09 | $239 |
| J9041 Injection, bortezomib, 0.1 mg | Office | 2,058 | 12 | $1.38 | $2,849 |
| 85025 Blood Count | Office | 1,406 | 244 | $7.59 | $11K |
| 36415 Venipuncture Blood Collection | Office | 1,345 | 246 | $8.63 | $12K |
| 80053 Clinical Chemistry | Office | 1,060 | 237 | $10.33 | $11K |
| 82784 Immunoassay | Office | 860 | 89 | $9.11 | $7,837 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 700 | 26 | $0.66 | $461 |
| 83615 Clinical Chemistry | Office | 587 | 213 | $5.90 | $3,464 |
| 96375 Injection Administration | Office | 558 | 86 | $10.96 | $6,114 |
| 83521 Immunoassay | Office | 518 | 69 | $16.93 | $8,767 |
| 96413 Chemotherapy Administration | Office | 420 | 86 | $91.70 | $39K |
By year: 2022 $3.2M for 147,339 services; 2023 $3.1M for 157,497 services; 2024 $3.7M for 161,378 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,406 | 244 | $7.59 | $11K |
| 36415 Venipuncture Blood Collection | 1,345 | 246 | $8.63 | $12K |
| 80053 Clinical Chemistry | 1,060 | 237 | $10.33 | $11K |
| 82784 Immunoassay | 860 | 89 | $9.11 | $7,837 |
| 83615 Clinical Chemistry | 587 | 213 | $5.90 | $3,464 |
| 83521 Immunoassay | 518 | 69 | $16.93 | $8,767 |
| 84165 Clinical Chemistry | 247 | 67 | $10.53 | $2,601 |
| 84550 Clinical Chemistry | 209 | 57 | $4.43 | $926 |
| 82728 Clinical Chemistry | 175 | 88 | $13.29 | $2,326 |
| 83735 Clinical Chemistry | 156 | 36 | $6.57 | $1,025 |
Medicare prescription drug claims, 2024
In 2024, the drug Brett T Brinker prescribed most often to Medicare patients was Acyclovir, with 905 prescriptions and refills. In total Brett T Brinker wrote 4,111 Medicare prescriptions that cost $20.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 905 | 1,298 | 194 | $14K |
| Dexamethasone Generic | 278 | 351 | 72 | $3,744 |
| Revlimid Lenalidomide | 248 | 248 | 42 | $4.2M |
| Pomalyst Pomalidomide | 132 | 132 | 25 | $3.0M |
| Calquence Acalabrutinib Maleate | 131 | 131 | 14 | $1.7M |
| Brukinsa Zanubrutinib | 129 | 129 | 17 | $1.5M |
| Lenalidomide Generic | 124 | 124 | 23 | $1.8M |
| Hydroxyurea Generic | 122 | 218 | 29 | $3,497 |
| Imbruvica Ibrutinib | 120 | 120 | 12 | $1.6M |
| Venclexta Venetoclax | 115 | 115 | 30 | $911K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 109 | 148 | 31 | $324 |
| Prednisone Generic | 100 | 100 | 48 | $247 |
| Prochlorperazine Maleate Generic | 88 | 93 | 60 | $1,125 |
| Eliquis Apixaban | 71 | 82 | 13 | $46K |
| Allopurinol Generic | 70 | 86 | 34 | $661 |
Brand drugs: - claims; generic drugs: 2,764 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Brett T Brinker $1,672 ($326 in general payments such as food, travel and fees and $1,345 for research) from 15 companies. The largest payer was F. Hoffmann-La Roche AG with $1,345.
| Company | Payments | Amount |
|---|---|---|
| F. Hoffmann-La Roche AG ROG.SW | 2 | $1,345 |
| Genzyme Corporation SNY | 4 | $96.74 |
| Merck Sharp & Dohme LLC MRK | 2 | $63.59 |
| Kyowa Kirin, Inc. 4151.T | 2 | $29.93 |
| BeOne Medicines USA, Inc. ONC | 1 | $29.32 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $28.55 |
| Amneal Pharmaceuticals LLC AMRX | 1 | $27.23 |
| Kite Pharma, Inc. GILD | 1 | $18.68 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $18.02 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $14.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.